Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Original Article
P. Sonneveld, M.A. Dimopoulos, M. Boccadoro, H. Quach, P.J. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, F. Gay, R. Mina, I.S. Nijhof, N.W.v.d. Donk, E. Katodritou, F. Schjesvold, A.S. Balari, L. Rosiñol, M. Delforge, W. Roeloffzen, T. Silzle, A. Vangsted, H. Einsele, A. Spencer, R. Hajek, A. Jurczyszyn, S. Lonergan, T. Ahmadi, Y. Liu, J. Wang, D. Vieyra, E.M.v. Brummelen, V. Vanquickelberghe, A. Sitthi-Amorn, C.J.d. Boer, R. Carson, P. Rodriguez-Otero, J. Bladé, and P. Moreau
N Engl J Med 2024;390:301-313
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Please sign in or create an account to take the course.